


CLAIMS

1.- Benzene-sulphonamide derivates having the general formula (I):



in which:

X represents a nitro, cyano, halogen group, eventually radioactive .

Y₁ represents a secondary or tertiary amino group, a sulphur or an oxygen

Y₂ represents a -NH group ,a nitrogen or an oxygen ;

Z represents oxygen, sulphur, -N-CN or -CH-NO₂; and

R₁ and R₂, which can be identical or different, represent each independently a linear or ramified alkyl group, saturated or unsaturated with 2 to 12 carbon atoms, an alicyclic group, saturated or unsaturated with 3 to 12 carbon atoms, eventually radioactive, an aryl group, substituted or not by one or several alkyl groups in C₁-C₄, nitro, cyano, trifluoromethyl, carboxy and halogen groups, or an arylalkyl group,

or R₁ and/or R₂ form with Y₁ and/or Y₂ a 5 to 7 membered heterocyclic group, saturated or unsaturated

with the exception of derivatives for which X is a nitro group, . Y₁ represents a secondary amine group (-NH-), Y₂ represents a -NH group, Z an oxygen, R₂, an isopropyl and R₁ an element selected in a group constituted of (m-toluyll, phenyl and cyclooctyl) and with the exception of N-[(2-CYCLOOCTYLAMINO-5-CYANOBeNZeNe)SULFONYL] N'-isopropyl urea. ;

2.- Derivate according to claim 1, characterized in that X represents nitro, cyano, bromo, iodine group.

3.- Derivate according to one or the other claims 1 and 2, characterized in that Y₁ represents a -NH group and Y₂ represents a -NH group or an oxygen atom.

4.- Derivate according to any of claims 1 to 3, characterized in that R₁ and R₂ represent each independently an ethyl, butyl, tert-butyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl, decyl, amyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 2-cyclohexenyl, m-toluy, o-toluy, p-toluy, phenyl, allyl, adamantyl, norbornyl; caproyl, 3-carboxyphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4,6-trimethylphenyl, furfuryl, benzyl or 1-phenylthyl group.

5.- Derivate according to one or the other claims 1 and 2, characterized in that R₂ and Y₂ form a homopiperidin group.

6.- Derivate according to one or the other claims 1 and 2, characterized in that R₁ and Y₁ form a morpholin or homopiperidin group.

7.- Derivate according to any of claims 1 to 6, characterized in that it is constituted by a salt chosen into the group formed by sodium salts, the potassic salts and the amino acid salts such as lysine, arginine.

8.- Derivate according to any of claims 1 to 7, characterized in that it is chosen in a group having:

N-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]N'-tert-butyl urea,

N-cyano-N'-[(2-metatoluylamino-5-nitrobenzene)sulfonyl]homopiperidinoamidine,

N-[(2-cycloheptylamino-5-nitrobenzene)sulfonyl]N'-cyclohexyl thiourea, and

N-[(cyclohexen-2-yl)-5-iodobenzene)sulfonyl]N'-pentyl urea.

9.- Pharmaceutical composition, characterized in that it includes a benzene sulphonamide derivate according to any of claims 1 to 8 in

TOPTO 0269559

10.- Use of a derivate according to any of claims 1 to 8, for the production of a medicament for the treatment and/or the prevention of the illnesses involving the thromboxan A₂ , such as for cardio-vascular and blood , pulmonary, reproduction and renal use.

Add